Delivery Order SPE2DB24D2003-SPE2DB25FXLQ3
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,625.80 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors. The contract represents a firm fixed price delivery order with an ultimate completion date of August 15, 2025, and was competitively awarded without set-aside provisions. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,702.33 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injectors. This firm fixed price, non-set-aside delivery order is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,706.08 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 20, 2025. This competitively awarded, firm fixed-price delivery order is set to be completed by August 21, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of the company's role as a critical pharmaceutical supplier to federal...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,232.68 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 mL pen injectors on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed price contract was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,573.99 for Zepbound 10 mg/0.5 mL pen injections on May 30, 2025, with completion targeted for June 2, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and identifies AmerisourceBergen's Conshohocken, Pennsylvania location as the place of performance. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections with a ceiling value of $5,141.16. This is a firm fixed-price delivery order with no set-aside designation, issued under a competitive procurement process. The order is set for completion by September 11, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania facility. This delivery order is a child contract issued...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $6,340.26 on September 17, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injections. The contract utilizes firm fixed-price pricing with no set-aside designation and is scheduled for completion by September 18, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on May 16, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens with a ceiling value of $2,104.73. This is a firm fixed-price delivery order with an ultimate completion date of May 19, 2025, and represents a non-set-aside competitive award. The order will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. As a child contract, this delivery order falls under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors with a ceiling value of $16,361.85. This firm fixed-price contract, which expires August 21, 2025, represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award was made through competitive procedures with no set-aside designation, and performance...
- The Defense Logistics Agency awarded a delivery order valued at $4,575.56 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on July 24, 2025, with an ultimate completion date of July 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and designates Conshohocken, Pennsylvania as the place of performance. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXLQ3Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,573.71 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on August 12, 2025. This firm fixed-price delivery order, which will be performed at the contractor's Conshohocken, Pennsylvania facility, represents a non-competitive set-aside and is scheduled for completion by August 13, 2025. The award falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion prime vendor agreement running through December 2026 that enables the pharmaceutical distributor to supply a comprehensive range of medications and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, maintains a substantial federal contract portfolio with the DLA focused on delivering brand-name and generic pharmaceuticals, vaccines, and medical devices across multiple therapeutic categories. The company's extensive experience fulfilling federal medical procurement requirements through competitive awards and its established prime vendor relationship with DLA positions it as a critical supplier for military and veteran healthcare systems. This specific delivery order for Zepbound, a GLP-1 receptor agonist used for weight management, reflects the contractor's ongoing role in supplying specialty pharmaceutical products to support Department of Defense healthcare initiatives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 8/12/25 |